




# NewCo Licensing



# NEWCO LICENSING

## PART 1. INNOVATIVE ASSETS

| Code  | Target                                  | Indications                                 | Preclinical | Ph I | Ph II | Ph III | NDA/BLA |
|-------|-----------------------------------------|---------------------------------------------|-------------|------|-------|--------|---------|
| UB013 | LAG3                                    | Solid tumors and lymphoma;<br>autoimmune    |             |      |       |        |         |
| UB014 | EGFR; CD3                               | Metastatic breast cancer;<br>gastric cancer |             |      |       |        |         |
| UB015 | Enzyme-controlled TAA; CD3              | Solid tumors                                |             |      |       |        |         |
| UB017 | IL-12 prodrug                           | Solid tumors                                |             |      |       |        |         |
| UB018 | ROR1; CD3                               | Lymphoma; breast cancer                     |             |      |       |        |         |
| UB019 | TAA; CD3                                | Hepatocellular carcinoma                    |             |      |       |        |         |
| UB020 | PD-1/IL-15 cytokine antibody conjudgate | Solid tumors                                |             |      |       |        |         |
| UB021 | CD3 bispecific antibody prodrug         | Solid tumors                                |             |      |       |        |         |
| UB023 | PD-L1; VEGF                             | Lung cancer; breast cancer                  |             |      |       |        |         |
| UB041 | HERV-K Env-TM                           | All cancer; autoimmune                      |             |      |       |        |         |

| Code  | Target                              | Indications                                       | Preclinical                       | Ph I | Ph II | Ph III | NDA/BLA |
|-------|-------------------------------------|---------------------------------------------------|-----------------------------------|------|-------|--------|---------|
| UB024 | KV1.3 (Topical)                     | Atopic dermatitis                                 | <div></div>                       |      |       |        |         |
| UB041 | 5-HT; DA                            | ASD                                               | <div><div></div><div></div></div> |      |       |        |         |
| UB026 | PI3K-mTOR-Akt pathway               | Melanoma; esophageal cancer, colorectal cancer    | <div></div>                       |      |       |        |         |
| UB027 | mTORC2                              | Neuroendocrine tumors; lung cancer; breast cancer | <div></div>                       |      |       |        |         |
| UB028 | FXIa                                | Thrombus                                          | <div></div>                       |      |       |        |         |
| UB029 | KV1.3 (Oral)                        | Inflammatory bowel disease                        | <div></div>                       |      |       |        |         |
| UB030 | cMyc                                | Gynecological tumors                              | <div></div>                       |      |       |        |         |
| UB040 | Multiple Targets                    | Immunostimulants                                  | <div></div>                       |      |       |        |         |
| UB042 | Agmatinase, Imidazoline Rc, NMDA Rc | ASD                                               | <div></div>                       |      |       |        |         |

| Code  | Target         | Indications                                                                 | Preclinical | Ph I | Ph II | Ph III | NDA/BLA |
|-------|----------------|-----------------------------------------------------------------------------|-------------|------|-------|--------|---------|
| UB044 | HER2           | Breast cancer                                                               | <div></div> |      |       |        |         |
| UB022 | HER2; Trop2    | Breast cancer; cervical cancer;<br>gastric cancer                           | <div></div> |      |       |        |         |
| UB031 | cMet/HER2      | Pancreatic cancer; lung cancer;<br>gastrointestinal<br>cancer; renal cancer | <div></div> |      |       |        |         |
| UB032 | Nectin-4/Trop2 | Bladder cancer; cervical<br>cancer; lung cancer                             | <div></div> |      |       |        |         |




| Code  | Target             | Indications                 | Preclinical | Ph I | Ph II | Ph III | NDA/BLA |
|-------|--------------------|-----------------------------|-------------|------|-------|--------|---------|
| UB011 | GLP-1 (Injection)  | Diabetes                    | <div></div> |      |       |        |         |
| UB045 | GLP-1 (Injection)  | Diabetes (+SGLT-2)          | <div></div> |      |       |        |         |
| UB045 | GLP-1 (Injection)  | Diabetes                    | <div></div> |      |       |        |         |
| UB047 | GLP-1; GCG         | Obesity                     | <div></div> |      |       |        |         |
| UB012 | GLP-1 (Injection)  | Obesity                     | <div></div> |      |       |        |         |
| UB048 | GLP-1; GCG         | MASH                        | <div></div> |      |       |        |         |
| UB049 | μ opioid receptor  | Opioid-induced constipation | <div></div> |      |       |        |         |
| UB050 | GCGR               | Congenital hyperinsulinism  | <div></div> |      |       |        |         |
| UB036 | GLP-1 (Oral)       | Diabetes; Obesity           | <div></div> |      |       |        |         |
| UB051 | GLP-1; GIP         | Diabetes; Obesity; MASH     | <div></div> |      |       |        |         |
| UB052 | GLP-1R; GIPR; GCGR | Diabetes; Obesity; MASH     | <div></div> |      |       |        |         |
| UB104 | GLP-1 (Oromucosal) | Diabetes; Obesity           | <div></div> |      |       |        |         |

| Code  | Target                            | Indications                      | Preclinical                                                        | Ph I | Ph II | Ph III | NDA/BLA |
|-------|-----------------------------------|----------------------------------|--------------------------------------------------------------------|------|-------|--------|---------|
| UB038 | TGF-β1/COX-2 (siRNA)              | isSCC; BCC                       | <div><div></div><div></div><div></div><div></div><div></div></div> |      |       |        |         |
| UB084 | (Oncolytic virus)                 | Metastatic refractory tumors     | <div><div></div><div></div><div></div><div></div><div></div></div> |      |       |        |         |
| UB098 | (HBV TCR-T)                       | Hepatocellular Carcinoma         | <div><div></div><div></div><div></div><div></div><div></div></div> |      |       |        |         |
| UB039 | TGF-β1/COX-2 (siRNA)              | Focal fact reduction             | <div><div></div><div></div><div></div><div></div><div></div></div> |      |       |        |         |
| UB099 | (HBV TCR-T)                       | Cholangio-carcinoma              | <div><div></div><div></div><div></div><div></div><div></div></div> |      |       |        |         |
| UB085 | (Oncolytic virus)                 | Metastatic refractory tumors     | <div><div></div><div></div><div></div><div></div><div></div></div> |      |       |        |         |
| UB100 | (HBV TCR-T)                       | Chronic Hepatitis B              | <div><div></div><div></div><div></div><div></div><div></div></div> |      |       |        |         |
| UB101 | (HPV TCR-T)                       | Cervical, Head & Neck Cancer     | <div><div></div><div></div><div></div><div></div><div></div></div> |      |       |        |         |
| UB089 | IL4R (siRNA)                      | Atopic dermatitis                | <div><div></div><div></div><div></div><div></div><div></div></div> |      |       |        |         |
| UB090 | Calcineurin/Fn14 (siRNA)          | Organ transplant; autoimmune     | <div><div></div><div></div><div></div><div></div><div></div></div> |      |       |        |         |
| UB091 | Glucosylceramide Synthase (siRNA) | Gaucher/Fabry                    | <div><div></div><div></div><div></div><div></div><div></div></div> |      |       |        |         |
| UB092 | Undisclosed (siRNA)               | Age-related macular degeneration | <div><div></div><div></div><div></div><div></div><div></div></div> |      |       |        |         |
| UB093 | Renin/AGT (siRNA)                 | Hypertension                     | <div><div></div><div></div><div></div><div></div><div></div></div> |      |       |        |         |

| Code  | Target              | Indications        | Preclinical | Ph I | Ph II | Ph III | NDA/BLA |
|-------|---------------------|--------------------|-------------|------|-------|--------|---------|
| UB094 | FcRn (siRNA)        | Myasthenia gravis  | <div></div> |      |       |        |         |
| UB095 | Undisclosed (siRNA) | Nephrotic syndrome | <div></div> |      |       |        |         |
| UB096 | SGLT2 (siRNA)       | Diabetes; ghout    | <div></div> |      |       |        |         |
| UB097 | Undisclosed (siRNA) | Melanoma           | <div></div> |      |       |        |         |
| UB102 | (EBV TCR-T)         | Solid tumor        | <div></div> |      |       |        |         |
| UB103 | (iPSC)              | Solid tumor        | <div></div> |      |       |        |         |



| Code  | Target | Indications       | Preclinical | Ph I | Ph II | Ph III | NDA/BLA |
|-------|--------|-------------------|-------------|------|-------|--------|---------|
| UB025 | cMyc   | Pancreatic cancer |             |      |       |        |         |



# **DISTRIBUTION TECH TRANSFER**

**PART 2. FINISHED DOSAGE FORMS**

A — Alimentary Tract and Metabolism

| Code  | FDF                                               | Indications                                                                                                                                  | Business Mode |
|-------|---------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|---------------|
| UB001 | Semaglutide Tablets                               | Diabetes; Obesity                                                                                                                            | Tech transfer |
| UB106 | Oral adsorptive charcoal                          | Chronic renal failure                                                                                                                        | Distribution  |
| UB116 | Palonosetron hydrochloride solution for injection | Prophylaxis or management of vomiting that results from emetogenic chemotherapy, and for the management of postoperative nausea and vomiting | Distribution  |

B — Blood and Blood Forming Organs

| Code  | FDF                                                                                     | Indications                                                              | Business Mode               |
|-------|-----------------------------------------------------------------------------------------|--------------------------------------------------------------------------|-----------------------------|
| UB007 | Recombinant Human Tissue-type Plasminogen Activator Derivative for Injection (Retepase) | Acute myocardial infarction; Acute ischemic stroke                       | Distribution; Tech transfer |
| UB009 | Recombinant Human Erythropoietin Injection (CHO cell; rhEPO alfa)                       | Anemia caused by CKD                                                     | Distribution; Tech transfer |
| UB037 | Enoxaparin Sodium Injection                                                             | Prophylaxis of venous thromboembolic diseases; deep venous thrombosis... | Distribution                |

C — Cardiovascular System

| Code  | FDF                            | Indications  | Business Mode |
|-------|--------------------------------|--------------|---------------|
| UB113 | Tolvaptan tablets              | Hyponatremia | Distribution  |
| UB117 | Levamlodipine Besylate Tablets | Hypertension | Distribution  |

D — Dermatological

| Code  | FDF                                  | Indications                                                                                                           | Business Mode |
|-------|--------------------------------------|-----------------------------------------------------------------------------------------------------------------------|---------------|
| UB086 | Lidocaine hydrochloride gel 2%       | Local anesthetics, for patients undergoing examinations and treatments via the urethra that require local anesthesia. | Distribution  |
| UB087 | Lidocaine 4% topical anorectal cream | For the temporary relief of pain, itching and burning associated with hemorrhoids and other anorectal disorders.      | Distribution  |

G — Genito Urinary System and Sex Hormones

| Code  | FDF                        | Indications          | Business Mode |
|-------|----------------------------|----------------------|---------------|
| UB118 | Sildenafil citrate tablets | Erectile dysfunction | Distribution  |
| UB119 | Tadalafil tablets          | Erectile dysfunction | Distribution  |

H

Systemic Hormonal Preparations, excl. Sex Hormones and Insulins

| Code  | FDF                  | Indications                                          | Business Mode |
|-------|----------------------|------------------------------------------------------|---------------|
| UB033 | Carbetocin Injection | To stop excessive bleeding after childbirth in women | Distribution  |

J

Antiinfectives for Systemic Use

| Code  | FDF                                                             | Indications                                                                                                                               | Business Mode |
|-------|-----------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|---------------|
| UB088 | Amoxicillin and Clavulanate Potassium for Oral Suspension (4:1) | Respiratory tract infections, acute bacterial otitis media, sinusitis, skin and skin structure infections, urinary tract infections, etc. | Tech transfer |
| UB111 | Caspofungin acetate for injection                               | Fungal injection                                                                                                                          | Distribution  |
| UB112 | Daptomycin for injection                                        | Complicated skin and skin structure infections                                                                                            | Distribution  |



L

Antineoplastic and Immunomodulating Agents

| Code  | FDF                                      | Indications                                                                                        | Business Mode               |
|-------|------------------------------------------|----------------------------------------------------------------------------------------------------|-----------------------------|
| UB008 | Recombinant Human Il-11 for Injection    | Thrombocytopenia caused by radiotherapy or chemotherapy                                            | Distribution; Tech transfer |
| UB034 | Thymalfasin Injection                    | Immune response booster                                                                            | Distribution                |
| UB107 | Megestrol Acetate Suspension             | Anorexia, Cachecia of cancer or AIDS patients;<br>Significant weight loss caused by unknown reason | Distribution                |
| UB108 | Paclitaxel (albumin-bound) for injection | Metastatic breast cancer; NSCLC                                                                    | Distribution                |
| UB109 | Irinotecan liposomal injection           | Metastatic adenocarcinoma                                                                          | Distribution                |
| UB110 | Pegaspargase injection                   | Acute lymphocytic leukemia                                                                         | Distribution                |

M

Musculo-Skeletal System

| Code  | FDF                 | Indications                                                                               | Business Mode |
|-------|---------------------|-------------------------------------------------------------------------------------------|---------------|
| UB105 | Pelubiprofen Tablet | Reduce symptoms of osteoarthritis, rheumatoid arthritis,<br>back pain (Lumbago) and fever | Distribution  |



N

Nervous System

| Code  | FDF                                             | Indications      | Business Mode |
|-------|-------------------------------------------------|------------------|---------------|
| UB114 | Bupivacaine liposomal injection                 | Local anesthetic | Distribution  |
| UB115 | Paliperidone palmitate ER injectable suspension | Schizophrenia    | Distribution  |

S

Sensory Organs

| Code  | FDF                                  | Indications                                                        | Business Mode |
|-------|--------------------------------------|--------------------------------------------------------------------|---------------|
| UB120 | Levofloxacin eye drops               | Eye infections                                                     | Distribution  |
| UB121 | Moxifloxacin hydrochloride eye drops | Eye infections                                                     | Distribution  |
| UB122 | Sodium hyaluronate eye drops         | Dry eye syndrome                                                   | Distribution  |
| UB123 | Bendazac Lysine Eye Drops            | Cataracts                                                          | Distribution  |
| UB124 | Diclofenac Sodium Eye Drops          | Reduce inflammation, pain, and light sensitivity after eye surgery | Distribution  |

# Meeting Request

Join us in bridging the gap between Chinese pharmaceutical innovation and global markets. Contact our NewCo team today to explore how we can unlock new possibilities together.



[bde@unibestcn.com](mailto:bde@unibestcn.com)



+86 (0)574 2785 5666



+86 152 5057 3086